Cardiology, GI, Derm: Which Specialties Drown Deepest in Prior Auth?

Prior authorization is a universal complaint, but it is not a uniform one. Cross-specialty, physicians and staff lose about 13 hours a week per physician to it AMA prior authorization, yet that average hides enormous variation: some specialties barely feel it, and some are effectively drowning. Understanding where you sit changes how seriously you should build for it.

The two drivers of burden

Burden concentrates along two axes, and a specialty can be heavy on either or both. The first is volume: specialties that order a lot of high-cost imaging and procedures, MRIs, CTs, PET scans, surgeries, generate a high number of authorization requests, because payers subject expensive imaging and procedures to review. Roughly a third of outpatient imaging orders now require prior authorization, so an imaging-heavy specialty processes a constant stream of them. The second is value and complexity: specialties that rely on high-cost drugs and biologics face fewer but far higher-stakes authorizations, frequently gated by step therapy, which forces patients through cheaper treatments first and generates multiple rounds of documentation. A single denied biologic authorization can represent thousands to tens of thousands of dollars. Peer-reviewed and industry analyses consistently name the acute cases as complex, time-sensitive specialties like oncology, cardiology, and rheumatology, where both drivers and real clinical stakes combine. Where your specialty falls on these two axes determines how heavy your burden is.

The specialties, ranked by burden

Here are the specialties that carry the heaviest prior authorization load, and what drives it for each.

These are broad patterns, not fixed rankings, individual practices vary by payer mix and the specific services they offer. But the shape holds: drug- and imaging-intensive specialties carry the load, and the ones heavy in both, orthopedics, cardiology, dermatology, feel it worst.

A closer look: cardiology, GI, derm

The three named in the title illustrate the two drivers well. Cardiology is a double-burden specialty: it combines a high volume of advanced imaging (stress tests, cardiac imaging) and interventional procedures with high-cost drugs like PCSK9 inhibitors, where prior auth is so onerous that a large share of prescribed patients never start the drug. Gastroenterology is a value story: it leans heavily on biologics for conditions like inflammatory bowel disease, which are gated by step therapy and can take weeks, around a month is commonly reported, to win approval, delaying care and tying up staff. Dermatology is the mixed case: a very high volume of outpatient procedures plus expensive biologics for psoriasis and other chronic conditions, so it carries both a steady stream of requests and a set of high-value, heavily scrutinized ones. In all three, prior auth is not an occasional interruption; it is woven through daily operations, which is exactly why they were named. The clinical stakes are real too, delays in these specialties translate into delayed diagnoses and treatments, documented across the prior auth statistics.

The dollars at stake

The burden is not just hours; it is real revenue exposure, and it scales with the specialty's drivers. Industry reporting puts the numbers in stark terms. In oncology, a single denied biologic or specialty-drug authorization can represent roughly $4,000 to $18,000 in revenue, so a handful of mishandled authorizations is a serious loss. In orthopedics, which saw prior auth denial volume climb sharply as imaging, surgical, and DME requirements expanded, annual prior-auth denial exposure for a small multi-provider group has been estimated in the tens of thousands to over a hundred thousand dollars. Across every specialty, each denied claim also costs to rework, around $57.23 on average and rising, detailed in the denial cost breakdown, on top of the reimbursement at risk. The pattern is clear: the higher your specialty sits on the volume and value axes, the larger the dollar figure attached to handling prior auth badly, and the faster a real system pays for itself. For a high-burden specialty, the question is not whether you can afford to build a prior auth system; it is whether you can afford not to.

Why payer mix changes everything

One variable can matter as much as specialty: your payer mix. Medicare Advantage and Medicaid managed care plans tend to apply more aggressive utilization management than commercial PPOs, so two practices in the same specialty can face very different prior authorization loads depending on who they serve. A rheumatology practice with a heavy Medicare Advantage panel may drown while a same-specialty practice on mostly commercial PPO patients merely treads water. This is why the specialty rankings are a starting point, not a verdict: layer your payer mix on top, and your real burden may be higher or lower than your specialty average suggests. It also means the reform landscape hits you unevenly, since the enforceable CMS rules reach exactly those managed-care plans, covered in the 2026 review. Know your own mix before you assume your burden matches the headline for your field.

What it means if you are one of them

If you practice a high-burden specialty, the takeaway is simple and consequential: prior authorization is not a nuisance to absorb, it is a core operational function to build for. At high volume, an ad hoc, fax-and-portal approach guarantees that authorizations age out, procedures get cancelled, and revenue leaks; at high value, a single mishandled biologic authorization is a large, high-stakes loss and a real patient harm. Either way, the answer is a genuine system: a tracked pipeline with aging alerts, clear ownership, and a resubmission and appeal process, the Zero-Slip system, paired with faster submission from these tactics, prevention from this guide, and the peer-to-peer and appeal tools in the P2P scripts and the appeal data. The higher your burden, the more a real system pays back, because in a drowning specialty, prior authorization is not overhead you tolerate, it is a revenue and care process you either run well or bleed from.

Concretely, a high-burden specialty should prioritize three things in that system. First, a tracked pipeline with aging alerts, so no authorization sits past its follow-up window and none ages out silently, which at high volume is where the biggest losses hide. Second, a fast, complete submission process, because in drug-heavy specialties the delay between order and approval directly delays care, and a clean first submission beats three rounds of back-and-forth. Third, a systematic appeal and peer-to-peer process, since high-value denials are worth fighting and most are overturned when they are, so leaving them unappealed forfeits real money. A generalist practice can sometimes get away with handling prior auth loosely; a high-burden specialty cannot, because the volume or the value turns every gap into a measurable loss. Build these three and prior auth shifts from a daily source of chaos to a managed process, which in a drowning specialty is the difference between bleeding and breaking even on the administrative side.

The data says which specialties those are. If yours is on the list, build accordingly.

Where to go next

• 40 Prior Auths Per Physician, Every Week: 8 Numbers From the AMA's 2025 Survey live

  8 verified prior authorization statistics for 2026, sourced to the AMA's 2025 survey, Experian,.

• The $57.23 Problem: What One Denial Really Costs to Rework live

  What it really costs to rework a denied claim: $57.23 and rising, plus delay and abandonment,.

• Independent Practice Operations in 2026: The Midyear Picture live

  The 2026 year in review for independent practices in numbers: ownership, prior auth, denials,.

Frequently asked questions